Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLC-3010
- Development stage
- Phase 2
- Lead developer
- Selecxine
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**SLC-3010** is an investigational, noncovalent antibody-cytokine conjugate developed by Selecxine for cancer immunotherapy. It consists of wild-type human interleukin-2 and TCB2, a humanized anti-IL-2 antibody that occupies the IL-2 interface used to bind CD25. This configuration biases IL-2 signaling toward IL-2 receptor beta and common gamma-chain signaling on CD8-positive effector T cells and natural killer cells, while limiting CD25-driven regulatory T-cell expansion. The program is designed to promote antitumor immunity through CD8 T-cell activation, regulatory T-cell modulation, and re-complexing of dissociated TCB2 with endogenous IL-2. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/il-2-anti-il-2-antibody-conjugate-slc-3010))
- Other names
- IL-2/TCB2 conjugate SLC-3010SLC 3010SLC3010SLC-3010
02
Targets
IL2RB (IL-2 receptor beta chain)IL-2 (Interleukin 2)IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on SLC-3010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC-3010.